| 1. | charlie4500kelly | |
| 2. | bcavage | |
| 3. | falkev01 | |
| 4. | geocansan | |
| 5. | DontGiveMeLip |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | bcavage 07/17/2018 Enters strategic alliance with Tasly Pharmaceutical Group; will receive $40 mln on closing |
| 2. | geocansan 08/30/2018 Mesoblast Provides Update on Transaction With Tasly Pharmaceutical Group |
| 3. | charlie4500kelly 05/31/2018 Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018 |
| 4. | bcavage 05/29/2018 Mesoblast Partners With Cartherics to Develop 'off-the-shelf' Cell-based Immunotherapies for Solid Cancers |
| 5. | falkev01 04/19/2018 Mesoblast Clinical Program Update for MPC-150-IM in Patients With Chronic Heart Failure |
| 6. | falkev01 02/21/2018 Big moves ahead |
| 7. | DontGiveMeLip 06/07/2018 H.C. Wainwright & Co. initiates coverage with Buy rating, $17 PT |
| 8. | charlie4500kelly 02/21/2018 OK let's see what happens now...... |
| 9. | charlie4500kelly 03/29/2018 Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment |
| 10. | charlie4500kelly 10/02/2018 Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
Mesoblast Limited
- MESO
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.